The FDA Group's Nick Capman sits down with Carlos Yuraszeck, an accomplished leader in biopharmaceutical compliance, operations, and quality assurance, with a specialized focus on driving innovation and efficiency in cell therapy manufacturing.
With over two decades of dedicated service in the biopharmaceutical industry, most recently serving as the Head of GMP Manufacturing at the Astellas Institute of Regenerative Medicine, Carlos provided profound insights into the pivotal role of phase-appropriate quality systems in managing drug development from research to commercialization. Our discussion focused on how these systems facilitate the rapid delivery of treatments to patients in urgent need.
Discussion points include:
Carlos Yuraszeck is a distinguished leader in biopharmaceutical compliance, operations, and quality assurance, specializing in cell therapy manufacturing. Over his extensive career spanning more than two decades, Carlos has significantly impacted the biopharmaceutical industry through his leadership in various pivotal roles. As the Executive Director of GMP Operations at Astellas Pharma US, he led the transformation of research groups into fully operational GMP manufacturing facilities. Earlier, as Senior Vice President of Technical Operations at Talaris Therapeutics, he managed operations focused on groundbreaking organ transplantation therapies. At Celgene, Carlos directed clinical production and supply, where he scaled up manufacturing operations to support the delivery of life-saving CAR T-cell therapies. His tenure in the industry is marked by a commitment to excellence, deep regulatory knowledge, and strategic oversight, which have driven the successful development and commercialization of novel therapies. Carlos's leadership style emphasizes collaboration, transparency, and continuous learning, aiming always to enhance patient outcomes and advance the field of biopharmaceuticals through innovative and efficient manufacturing practices.
Navigating FDA Regulations for SaMD AI and Machine Learning with Adam Foresman
Leading Through Transition: Strategic Insights from Novartis's Front Lines
Real Talk on Remote Leadership with Nick Klingensmith
Audit and FDA Inspection Readiness Best Practices with Divya Gowdar
Mastering the TMF: Ensuring GCP Compliance and Inspection Readiness with Donna Dorozinsky
The Startup's Guide to Setting Up Cell Therapy Manufacturing: Navigating Regulations, Resources and Timelines
A Blueprint for Quality Culture with Vincent Cafiso
An FDA Inspection Survival Guide with Jonathan Wacks
Clinical Data Standards in Focus: SDTM Compliance with Sunil Gupta
The Link Between Quality Culture and QA Communication Pathways with David Marks
Mastering Medical Device Supplier Management with Paul Hakamaki
Recent FDA Enforcement Trends with George Toscano
Growing Your Career in RA/QA with Jessica Smith Beaver, PhD
Drug Delivery System Innovation and Leadership with Steve Knowles
Motivating Technical Teams in the Life Sciences: A Conversation with Rick Beatty
Cross-Cultural Pharma: Mike Martin's Experiences from Puerto Rico to China
Courageous Leadership to Reinvent Our Healthcare System
The Critical Role of 'Hyper-Targeting' in Rare Disease Drug Development
A Journey into Life Sciences Investment: Strategies, Challenges, and Opportunities with Sal Buscemi
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths